Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
OCOculis Holding AG logo

Oculis Holding AG (OCS)

NASDAQ Global Market · Currency in USD
$7.90 ▼ -0.19 (-2.35%)
At close: Oct 23, 4:00 PM ET. Market closed.
$8.43 ▲ +0.53 (+6.76%)
After hours: Oct 23, 7:34 PM ET

Summary

Previous Close
$8.09
Open
$8.04
Day's Range
$7.87 – $8.07
52 Week Range
$7.11 – $34.48
Volume
294,727
Avg. Volume
314,354
Market Cap
$486.55M
Beta (5Y Monthly)
0.23
PE Ratio (TTM)
--
EPS (TTM)
-$1.30
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$36.75

Profile: Oculis Holding AG

Sector
Healthcare
Industry
Biotechnology
Full-time employees
60
CEO
Riad Sherif
Website
oculis.com

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.49 · Revenue est. $247.23K
DateEst.Actual
Aug 6, 2026-$0.48-$0.20Beat
May 11, 2026-$0.49-$0.63Miss
Mar 3, 2026-$0.48-$0.51Miss
Nov 10, 2025-$0.50-$0.40Beat
Aug 21, 2025-$0.53-$0.59Miss
May 8, 2025-$0.51-$0.77Miss

Analyst view

Consensus price target
$36.75 ▲ +365.2%
Range $26.00 – $45.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on OCS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.